Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by International Assets Investment Management LLC

International Assets Investment Management LLC raised its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 1,098.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,494 shares of the company’s stock after buying an additional 4,119 shares during the period. International Assets Investment Management LLC’s holdings in Nurix Therapeutics were worth $101,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of NRIX. GAMMA Investing LLC boosted its position in Nurix Therapeutics by 299.8% during the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after acquiring an additional 3,424 shares during the last quarter. EntryPoint Capital LLC acquired a new position in shares of Nurix Therapeutics during the 1st quarter worth approximately $123,000. ProShare Advisors LLC boosted its holdings in shares of Nurix Therapeutics by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after purchasing an additional 998 shares during the last quarter. Dark Forest Capital Management LP acquired a new stake in shares of Nurix Therapeutics in the second quarter valued at approximately $201,000. Finally, Caxton Associates LP acquired a new stake in shares of Nurix Therapeutics in the first quarter valued at approximately $225,000.

Nurix Therapeutics Trading Up 0.9 %

Shares of NRIX opened at $27.24 on Friday. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -9.51 and a beta of 2.20. The firm’s fifty day simple moving average is $24.26 and its 200-day simple moving average is $20.55. Nurix Therapeutics, Inc. has a twelve month low of $4.96 and a twelve month high of $28.42.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The company had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. On average, analysts predict that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. JPMorgan Chase & Co. raised their target price on Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Royal Bank of Canada cut their price objective on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Jefferies Financial Group began coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $41.00 target price on the stock. Barclays raised their price target on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. Finally, Robert W. Baird initiated coverage on Nurix Therapeutics in a report on Friday, September 6th. They issued an “outperform” rating and a $26.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, Nurix Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $29.40.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00. Following the sale, the chief financial officer now owns 31,002 shares of the company’s stock, valued at approximately $781,870.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Gwenn Hansen sold 3,437 shares of Nurix Therapeutics stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $83,519.10. Following the sale, the insider now owns 50,670 shares of the company’s stock, valued at $1,231,281. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 20,000 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.22, for a total value of $504,400.00. Following the transaction, the chief financial officer now directly owns 31,002 shares of the company’s stock, valued at approximately $781,870.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 57,321 shares of company stock valued at $1,414,409 over the last three months. 9.80% of the stock is owned by corporate insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.